Diabetes, Vol 36, Issue 7 813-821, Copyright © 1987 by American Diabetes Association

ARTICLES

Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration

JR Williamson, K Chang, RG Tilton, C Prater, JR Jeffrey, C Weigel, WR Sherman, DM Eades and C Kilo

125I-labeled albumin permeation (IAP) has been assessed in various tissues in spontaneously diabetic insulin-dependent female BB/W rats and in male Sprague-Dawley rats with severe or mild forms of streptozocin-induced diabetes (SS-D and MS-D, respectively). In BB/W diabetic rats and in rats with SS-D, indices of IAP were significantly increased in tissues and vessels predisposed to diabetic vascular disease in humans, including the eyes (anterior uvea, posterior uvea, and retina), sciatic nerve, aorta, kidney, and new vessels formed after induction of diabetes. No evidence of increased IAP was observed in heart, brain, testes, or skeletal muscle in BB/W or SS-D rats. In MS-D rats, indices of IAP were increased only in the kidney and in new vessels formed after the onset of diabetes. Marked tissue differences were observed in the effects of two structurally different aldose reductase inhibitors (sorbinil and tolrestat) and of castration on diabetes-induced increases in IAP and in tissue levels of polyols in SS-D rats. Both aldose reductase inhibitors and castration completely prevented diabetes-induced increases in IAP in new vessels and in sciatic nerve in BB/W and SS-D rats. Both aldose reductase inhibitors also markedly decreased IAP in the anterior uvea (approximately 85%), posterior uvea (approximately 65-75%), retina (approximately 65-70%), and kidney (approximately 70-100%); castration reduced IAP in the anterior uvea (approximately 55%), kidney (approximately 50%), and retina (approximately 30%) but had no effect on the posterior uvea. The diabetes-induced increases in IAP in the aorta were reduced only slightly (approximately 20%) by aldose reductase inhibitors and castration.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Schramm, T. Dinh, and A. Veves Microvascular changes in the diabetic foot. International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 149 - 159. [Abstract] [PDF]

				A. Inada, K. Nagai, H. Arai, J.-i. Miyazaki, K. Nomura, H. Kanamori, S. Toyokuni, Y. Yamada, S. Bonner-Weir, G. C. Weir, et al. Establishment of a Diabetic Mouse Model with Progressive Diabetic Nephropathy Am. J. Pathol., August 1, 2005; 167(2): 327 - 336. [Abstract] [Full Text] [PDF]

				A. J. Barber, D. A. Antonetti, T. S. Kern, C. E. N. Reiter, R. S. Soans, J. K. Krady, S. W. Levison, T. W. Gardner, and S. K. Bronson The Ins2Akita Mouse as a Model of Early Retinal Complications in Diabetes Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 2210 - 2218. [Abstract] [Full Text] [PDF]

				A. J. Barber and D. A. Antonetti Mapping the Blood Vessels with Paracellular Permeability in the Retinas of Diabetic Rats Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5410 - 5416. [Abstract] [Full Text] [PDF]

				G. Booth, T. J. Stalker, A. M. Lefer, and R. Scalia Mechanisms of Amelioration of Glucose-Induced Endothelial Dysfunction Following Inhibition of Protein Kinase C In Vivo Diabetes, May 1, 2002; 51(5): 1556 - 1564. [Abstract] [Full Text] [PDF]

				S. B. Koevary, J. Nussey, and S. Lake Accumulation of Topically Applied Porcine Insulin in the Retina and Optic Nerve in Normal and Diabetic Rats Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 797 - 804. [Abstract] [Full Text] [PDF]

				S. Y. Yuan, E. E. Ustinova, M. H. Wu, J. H. Tinsley, W. Xu, F. L. Korompai, and A. C. Taulman Protein Kinase C Activation Contributes to Microvascular Barrier Dysfunction in the Heart at Early Stages of Diabetes Circ. Res., September 1, 2000; 87(5): 412 - 417. [Abstract] [Full Text] [PDF]

				M. Meier and G. L King Protein kinase C activation and its pharmacological inhibition in vascular disease Vascular Medicine, August 1, 2000; 5(3): 173 - 185. [Abstract] [PDF]

				E. M Rocha, L A. Wickham, L. A da Silveira, K. L Krenzer, F.-S. Yu, I. Toda, B. D Sullivan, and D. A Sullivan Identification of androgen receptor protein and 5alpha -reductase mRNA in human ocular tissues Br. J. Ophthalmol., January 1, 2000; 84(1): 76 - 84. [Abstract] [Full Text]

				C. Renard, O. Chappey, M. P. Wautier, M. Nagashima, J. Morser, J. M. Scherrmann, and J. L. Wautier The Human and Rat Recombinant Receptors for Advanced Glycation End Products Have a High Degree of Homology but Different Pharmacokinetic Properties in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1458 - 1466. [Abstract] [Full Text]

				A. M. Schmidt, S. D. Yan, J.-L. Wautier, and D. Stern Activation of Receptor for Advanced Glycation End Products : A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis Circ. Res., March 19, 1999; 84(5): 489 - 497. [Abstract] [Full Text] [PDF]

				C. Renard, O. Chappey, M.-P. Wautier, M. Nagashima, E. Lundh, J. Morser, L. Zhao, A.-M. Schmidt, J.-M. Scherrmann, and J.-L. Wautier Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats Mol. Pharmacol., July 1, 1997; 52(1): 54 - 62. [Abstract] [Full Text]